Advanced Liquid Logics

//Advanced Liquid Logics

Project Description

Advanced Liquid Logic, Inc is committed to the development of cost-effective automation solutions for complex bioassay workflows.  Our proprietary digital microfluidics technology will accelerate and improve life science research, as well as broaden the availability of molecular diagnostics.  On July 23, 2013, ALL was acquired by Ilumina (NASDAQ:ILMN)

Dr. Michael Pollack and Dr. Vamsee Pamula founded the company in 2004 and remain engaged full time with the company as co-CTO’s. Vamsee and Michael developed the core technology while completing their doctorates and post doctoral research at Duke University’s Pratt School of Engineering. The company is led by an experienced CEO, Richard West, who joined ALL in 2005. Rich has 15 years of experience as a CEO and a cumulative 30 years in business and product development management.

Since our founding ALL has focused on improving the capabilities and manufacturability of our core technology – digital microfluidics. Below, we list a few of our recent accomplishments:

ALL has been recognized by both Frost and Sullivan (Lab-on-a-Chip Company of the Year) and the Wall Street Journal (Technology Innovation Award) for its groundbreaking, disruptive technology and its progress in demonstrating its utility.

ALL has demonstrated – with performance comparable to or better than traditional systems – sample preparation, immunoassays, PCR, enzymatic assays, clinical chemistry, and DNA sequencing on its lab-on-a-chip platform.

ALL has created a talented and engaged team that includes senior executives in manufacturing, product development, human resources, and quality and regulatory affairs. The company has also developed numerous value-adding academic collaborations and an active advisory board.

ALL has implemented its lab-on-a-chip technology using low cost, manufacturable printed circuit board technology and has invested in facilities and equipment to scale up to high volume.

ALL has assembled a comprehensive intellectual property portfolio in the area of droplet-based digital microfluidics. The company owns or controls over 50 issued patents, has over 200 active patent filings and has made several strategic acquisitions and in-licensing deals.


Related News

New LiftOff Provider Network Sponsorship Opportunities

Early stage companies who receive federal government grants, including Small Business Administration SBIR/STTR grants, have [...]

Sponsorship Engagement Opportunities with STEM Students

FIRST North Carolina and First Flight’s Hangar6 have joined forces to help STEM students prepare [...]


First Flight Venture Center (First Flight), a Research Triangle Park-based science and technology incubator for early [...]

Hangar6 Prototyping Facility Accepting New Members

Hangar6, is North Carolina’s premier prototyping facility. It is a unique space offering advanced prototyping and design assistance [...]

GreenLight Biosciences: Targeting Pesky Pests

There are estimated to be 10 quintillion insects in the world so it’s no wonder [...]

Dignify Therapeutics Announces Patent for treatment of voiding dysfunction

Dignify Therapeutics, LLC, a leading developer of therapies for bladder and bowel dysfunction, announces the [...]

OCTOBER 25th: First Flight’s Annual Pig Pickin’ Event

You are invited to our annual Pig Pickin', a casual event for First Flight companies, [...]


First Flight Venture Center (First Flight), a Research Triangle Park-based science and technology incubator for [...]

FDA Approves New FemTech Device to Enhance Quality of Care for the Uterus

The Luminelle DTx Hysteroscopy System has received its 510(k) clearance from the FDA with a [...]

Project Details